Serum defensin levels in patients with systemic sclerosis

Autor: Hatice Pasaoglu, Ozge Tugce Pasaoglu, Ozkan Varan, Hamit Küçük, Berna Goker, Tugce Emiroglu Gedik, Mehmet Akif Ozturk, Seminur Haznedaroglu, Abdurrahman Tufan
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Male
lcsh:Diseases of the musculoskeletal system
Pathogenesis
Gastroenterology
Scleroderma
Alpha defensin
Pulmonary function testing
Plasma
Idiopathic pulmonary fibrosis
Alpha-Defensins
0302 clinical medicine
Medicine
Defensin
medicine.diagnostic_test
integumentary system
Interstitial lung disease
Beta defensin
Classification
Respiratory Function Tests
Beta-Defensin
C-Reactive Protein
Erythrocyte sedimentation rate
Systemic sclerosis
Antimicrobial peptides
Female
Adult
lcsh:Immunologic diseases. Allergy
medicine.medical_specialty
alpha-Defensins
Ll-37
Blood Sedimentation
03 medical and health sciences
Rheumatology
Internal medicine
Humans
Autoantibodies
030203 arthritis & rheumatology
Inflammation
Scleroderma
Systemic
business.industry
medicine.disease
030104 developmental biology
Release
Case-Control Studies
lcsh:RC925-935
business
Peptides
lcsh:RC581-607
Diffuse panbronchiolitis
Zdroj: Advances in Rheumatology, Vol 60, Iss 1, Pp 1-5 (2020)
Advances in Rheumatology, Volume: 60, Article number: 54, Published: 13 JAN 2021
ISSN: 2523-3106
Popis: BackgroundSystemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and lung as well as involvement of kidney, gastrointestinal system and heart. Aetiology and exact mechanism of disease is poorly understood. The association between antimicrobial peptides (AMPs) and other diseases such as idiopathic pulmonary fibrosis, diffuse panbronchiolitis, pulmoner alveolar proteinosis and psoriasis have been reported. A small number of studies have examined the role of AMPs on autoimmune diseases which has not been studied in scleroderma yet. We aimed to investigate AMP serum levels and their association with disease characteristics of SSc.MethodsForty-two patients (40 female, mean age 42 years) and 38 healthy subjects (32 female, mean age 38 years) were enrolled. For SSc patients, the following data were recorded: disease subset (limited/diffuse), autoantibodies (antinuclear, anti-centromere (ACA), and anti-SCL-70), blood tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP), modified Rodnan skin score, presence and history of digital ulcers, kidney, gastrointestinal disease and lung involvement assessed by computed tomography and pulmonary function tests. Association between serum AMPs and disease characteristics were analysed.ResultsTwenty-nine of the patients had diffuse (69%) and 13 of the patients had limited (31%) systemic sclerosis. Average disease duration was 5.5 years. Pulmonary involvement was detected in 20 patients (47.6%). Serum concentration of alpha defensin was higher than healthy subjects (563 ± 415 vs 377 ± 269 ng/mL,p = 0.02). However, no difference was observed for beta-1 and beta-2 defensins in SSc patients and healthy controls. In sub-group analysis patients with interstitial lung disease had higher levels of alpha defensin than those without lung involvement (684 ± 473 vs 430 ± 299 ng/ml,p = 0.04). There was also correlation between alfa defensin serum concentrations and CRP (r = 0.34).ConclusionsAlpha defensin levels are increased in scleroderma patients and correlated with lung involvement indicating a role in the pathogenesis of disease.Trial registrationThis study is not a clinical trial study.
Databáze: OpenAIRE
Externí odkaz: